Multi-tiered in silico evaluation identifies Sarsasapogenin as a promising ERα-targeted phytochemical against breast cancer.
Predicted phase-I hydroxylation does not abolish ERα engagement, which argues for evaluating biotransformation products alongside the parent compound in computational screening of plant sapogenins.